Skip to Main Content
  • About Us
  • People
  • Capabilities
  • News & Insights
  • Events
  1. Industries
  2. Startups

Startups

stock image of pharma test tubes in lab

Shipman is a leader in the start-up and emerging growth company space market and advises hundreds of early stage companies with respect to all matters of the business lifecycle, from formation to exit. We combine a practical and flexible approach to early stage companies with the experience and skills of seasoned business and finance, private equity, securities, internet-based business, intellectual property and mergers and acquisitions lawyers. Shipman’ s national network of influential contacts, including VCs, angels, corporate investors and thought leaders provides our clients access to intellectual capital and financial resources appropriate for their individual needs and goals.

Shipman serves clients in various industries, including life sciences and healthcare, information technology, Internet services and e-commerce, cybersecurity, consumer goods, energy and alternative energy, education, engineered materials, telecommunications and new media. We pride ourselves on our practical, cost-effective, business-oriented advice and our broad industry knowledge and experience.

As part of our commitment to the success of the new generation of innovators and entrepreneurs, Shipman offers a proprietary, alternative fee program called "Synergy" for qualified startups. For more information about our Synergy Program, click here or on the Synergy button at left. Our plan is designed to help startups and entrepreneurs prepare for a successful launch while overcoming the challenges of limited resources, time, and funding.

Our representation of clients includes:

  • Organizational matters among founders - choice of entity and other structuring issues, equity issuances, shareholder and operating agreements
  • Business advisory services - corporate governance, board of directors and shareholder matters, employee issues, tax strategies, intellectual property protections, and general contracting including the development of form agreements such as NDAs, Invention Assignment Agreements and Consulting Agreements
  • Early-stage finance – priced equity rounds, convertible debt and SAFE financing, venture debt, and angel investments
  • Equity compensation matters
  • Commercialization of products and technology - licensing, product distribution, joint ventures, strategic alliances
  • Technology development and licensing - technology transfer, R&D agreements, licensing
  • Intellectual property protection - trade secrecy agreements, copyright, trademark and domain name protection, trademark prosecution and maintenance, intellectual property litigation
  • Web site development, hosting and privacy policies;
  • Business succession planning - estate and gift tax planning for entrepreneurs and their families.

Shipman is proud to support and participate in programs and events with the following bioscience and technology organizations: ABCT (Accelerator for Biosciences in CT and NY), BioCT, Connecticut Innovations, CT Technology Council, Crossroads Venture Group, Yale Office of Cooperative Research (Innovation Summit and PitchFest), University of Connecticut TIP, and Women in Bio.

Shipman is proud to support and participate in programs and events with the following bioscience and technology organizations: ABCT (Accelerator for Biosciences in CT and NY), BioCT, Connecticut Innovations, CT Technology Council, Crossroads Venture Group, Yale Office of Cooperative Research (Innovation Summit and PitchFest), University of Connecticut TIP, and Women in Bio.

Experience

General

Biotech Company Pioneers Technology For New Class of Drugs

Dormer Stephen, Co-Chair of our Business and Finance practice area, structured and negotiated this deal for Arvinas. Arvinas is built on the research of Craig Crews, PhD, Lewis B. Cullman Professor of Molecular, Cellular and Developmental Biology and professor of Chemistry and Pharmacology at Yale University. The new drugs being developed by Arvinas would induce a cell’s own protein-degradation capabilities to bind to a particular protein and “label” it for degradation, thus removing a protein from the system entirely. This contrasts to a more traditional drug development approach that inhibits proteins. However, only 25 percent of the body’s 20,000 proteins can be inhibited. Proteins that cannot be inhibited can potentially be degraded using Arvinas’ approach, radically expanding the number of disease-causing proteins that can become the targets of new drugs.

Represented biotech company in $3 million Series A financing

Represented numerous software, technology and life sciences companies in connection with formation and general corporate matters

Represented biotech company in $15 million Series A financing

Load More +

Insights

Events

November 8, 2018

Alternative Funding Sources & Insights

→

November 7, 2018

Marcum New England Life Sciences and Biotech Summit

→
Load More +

Primary Contacts

J. Dormer Stephen bio photo
J. Dormer Stephen

Partner

203.836.2803

dstephen@goodwin.com
Matthew Monteith Bio Photo
Matthew J. Monteith

Partner

860.251.5784

mmonteith@goodwin.com
See All Related Professionals
  • -

    Synergy Widget

Keep in Touch

Stay current with our latest insights

Manage Subscriptions
  • Lawyers
  • Capabilities
  • Events
  • Diversity, Equity and Inclusion
  • Pro Bono and Community
  • Blogs and Resource Centers
  • Insights
  • Podcasts
  • Dobbs Decision Resource Center
  • About Us
  • Careers
  • Contact Us
  • Disclaimer
  • Privacy Policy
  • Terms of Use
  • Accessibility Statement

© Shipman & Goodwin LLP™ 2025. All Rights Reserved